GlassScriptPhysician profile
Usman Zaheer
NPI 1104319383
$5,344.08
in general payments reported to CMS, 2019-2025
50 companies · $1,920 in 2025
The $1,920 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $164 · 2022: $573 · 2023: $1,299 · 2024: $1,387 · 2025: $1,920.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,509 · Education: $98.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,508.80 |
| Education | $98.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $461.75 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $380.44 | 2022-2025 | Opdivo, Reblozyl, Opdualag |
| Astrazeneca Pharmaceuticals LP | $366.67 | 2022-2025 | Enhertu, Lynparza, Calquence |
| Daiichi Sankyo INC. | $354.29 | 2022-2025 | Enhertu, Injectafer, Datroway |
| Seagen INC. | $265.99 | 2022-2023 | Adcetris |
| Celgene Corporation | $253.84 | 2022-2025 | Reblozyl, Opdualag |
| Glaxosmithkline, LLC. | $250.08 | 2023-2025 | Zejula, Jemperli, Blenrep |
| Janssen Biotech, INC. | $210.33 | 2023-2025 | Darzalex, Imbruvica, Rybrevant |
| Pfizer INC. | $197.46 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $183.59 | 2022-2025 | Keytruda, Welireg, Lynparza |
| Pharmacyclics LLC, An Abbvie Company | $155.31 | 2023 | Imbruvica, Epkinly |
| Takeda Pharmaceuticals U.S.A., INC. | $142.42 | 2024-2025 | Ninlaro, Alunbrig, Iclusig |
| Genmab U.S., INC. | $125.00 | 2023 | Tivdak |
| Abbvie INC. | $118.36 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $117.50 | 2023-2025 |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $116.25 | 2023-2024 | Retevmo, Jaypirca, Verzenio |
| Incyte Corporation | $113.34 | 2022-2025 | Jakafi |
| Astellas Pharma US INC | $105.54 | 2022-2025 | Xtandi |
| Alexion Pharmaceuticals, INC. | $105.28 | 2024-2025 | Ultomiris |
| Kite Pharma, INC. | $96.09 | 2021 | |
| Genentech USA, INC. | $93.25 | 2022-2025 | Tecentriq, Polivy, Lunsumio |
| Karyopharm Therapeutics INC. | $71.89 | 2023 | Xpovio |
| Jazz Pharmaceuticals INC. | $70.05 | 2021-2023 | |
| Genentech, INC. | $68.74 | 2024 | Polivy, Lunsumio, Columvi |
| Tersera Therapeutics LLC | $64.60 | 2024-2025 | Zoladex |
| Beigene USA, INC. | $58.43 | 2023-2024 | Brukinsa, Tevimbra |
| Agios Pharmaceuticals, INC. | $57.42 | 2025 | Pyrukynd |
| Genzyme Corporation | $53.93 | 2025 | |
| Array Biopharma INC | $47.89 | 2025 | Braftovi, Lorbrena, Tukysa |
| Biosense Webster, INC. | $46.23 | 2025 | Carto 3 |
| Gilead Sciences, INC. | $43.42 | 2024-2025 | Trodelvy |
| Mirati Therapeutics, INC. | $43.02 | 2023 | Krazati |
| Servier Pharmaceuticals LLC | $42.52 | 2024-2025 | |
| Ge Healthcare | $39.43 | 2025 | |
| Sobi, INC | $39.03 | 2023-2025 | |
| Azurity Pharmaceuticals, INC. | $36.85 | 2024-2025 | Vivimusta, Danziten |
| Rigel Pharmaceuticals, INC. | $36.22 | 2024-2025 | Rezlidhia, Tavalisse, Gavreto |
| Springworks Therapeutics, INC. | $30.21 | 2024 | Ogsiveo |
| Eisai INC. | $29.47 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $28.84 | 2024 | Onivyde |
| Sumitomo Pharma America, INC. | $28.71 | 2025 | Orgovyx |
| Taiho Oncology, INC. | $28.67 | 2024-2025 | |
| Tempus Ai, INC | $27.60 | 2024 | |
| Fennec Pharmaceuticals, INC. | $24.65 | 2024 | Pedmark |
| Coherus Oncology, INC. | $23.66 | 2024 | |
| Puma Biotechnology, INC. | $20.34 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $19.65 | 2023 | Libtayo |
| Pharmaessentia USA Corporation | $19.60 | 2025 | Besremi |
| Secura Bio, INC. | $15.22 | 2024 | Copiktra |
| Horizon Therapeutics Plc | $15.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Usman Zaheer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.